RESUMO
Although renal pelvic and ureteral urothelial carcinoma share similarities in their origins, disparities on a genetic and clinical level make them divergent entities. Clinical information from the Surveillance, Epidemiology, and End Results (SEER) database was used to validate the characteristics and molecular subtypes using single-center data, which were compared between the two types of muscle-invasive tumors. Simultaneously, to expand the sample size for further verification, we explored a deep learning algorithm to correctly classify molecular subtypes from H&E histology slides. We suggested that the renal pelvic group might have a proclivity towards luminal and the ureter towards basal and P53-like. Furthermore, we explore the heterogeneity of matrix and immune tumor microenvironment, and the ureteral group had more immune cell infiltration and higher stiffness. Collectively, these results showed that muscle-invasive upper tract urothelial carcinoma exist in distinct properties of clinical characteristics, molecular subtype, and tumor microenvironment.
Assuntos
Carcinoma de Células de Transição , Neoplasias Renais , Neoplasias Ureterais , Neoplasias da Bexiga Urinária , Humanos , Carcinoma de Células de Transição/patologia , Neoplasias Renais/patologia , Pelve Renal/patologia , Músculos/patologia , Microambiente Tumoral , Neoplasias Ureterais/patologia , Neoplasias da Bexiga Urinária/patologiaRESUMO
Drug metabolism and pharmacokinetics (DMPK) are the science to study the process of drug absorption, distribution, metabolism and excretion. It is very important to evaluate the characteristics of DMPK for the early development of drugs and the later clinical precision medication. The innovative construction of DMPK models promotes the development and improvement of drug evaluation system. Based on our research results, this review summarized the latest progress and application of innovative DMPK models, focusing on the following two aspects: (1) CRISPR/Cas9 gene editing rat models, including Cyp2e1
RESUMO
OBJECTIVE:To observe the clinical efficacy and safety of the effect of desloratadine citrate disodium in the decre-mental treatment of chronic urticaria. METHODS:212 patients with chronic urticaria were randomly divided into decremental treat-ment group and control group. Decremental treatment group was treated with Desloratadine citrate disodium capsules 17.6 mg in the first week,orally,qd;8.8 mg in the second week,orally,qd;8.8 mg in the third week,orally,qod;and 8.8 mg in the fourth week,orally,q3d. Control group was treated with Desloratadine citrate disodium capsules 8.8 mg,orally,qd. The treatment course for both groups was 4 weeks. The clinic data was observed,including clinical efficacy,and serum IgE,clinical symptom scores before and after treatment,recurrence rate and incidence of adverse reactions. RESULTS:The differences were not statistical-ly significant in the total effective rate and incidence of adverse reactions between 2 groups(P>0.05). The recurrence rate in decre-mental treatment was significantly lower than control group(P0.05). CONCLUSIONS:Desloratadine citrate disodium have similar clinical efficacies and safety in the decremental treatment and conventional treatment of chronic urticaria. However,decremental treatment of deslo-ratadine citrate disodium is better than conventional treatment in terms of improving the level of IgE.